Adagene Inc (ADAG)

Adagene Inc. is a clinical-stage biotechnology company focused on discovering, developing, and producing monoclonal antibody therapeutics for cancer. The listed security is an ADR, structured as a depositary receipt representing the company’s common stock on Nasdaq. Adagene’s development pipeline includes several oncology candidates at different stages of clinical and preclinical testing. Its lead program, ADG126, is a masked fully human anti-CTLA-4 monoclonal antibody in phase 1b/2 studies. Other pipeline assets include ADG116 for advanced or metastatic solid tumors, ADG206 for advanced metastatic solid tumors, ADG104, an anti-PD-L1 antibody in phase 2 development, and ADG125, an anti-CSF-1R antibody also in phase 2. The company is additionally advancing preclinical programs such as ADG138, ADG152, ADG153, and CD28 T-cell engager candidates. Adagene was incorporated in 2011 and is headquartered in Suzhou, China.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.